Pub Date : 2020-10-20eCollection Date: 2020-12-01DOI: 10.1097/IM9.0000000000000040
Oluwafolajimi A Adesanya, Christabel I Uche-Orji, Yeshua A Adedeji, John I Joshua, Adeniyi A Adesola, Chibuike J Chukwudike
Following the discovery of the Bacillus Calmette-Guerin (BCG) vaccine, its efficacy against Mycobacterium tuberculosis was soon established, with several countries adopting universal BCG vaccination schemes for their populations. Soon, however, studies aimed to further establish the efficacy of the vaccine in different populations discovered that the vaccine has a larger effect in reducing mortality rate than could be explained by its effect on tuberculosis alone, which sparked suggestions that the BCG vaccine could have effects on other unrelated or non-mycobacterial pathogens causing diseases in humans. These effects were termed heterologous, non-specific or off-target effects and have been shown to be due to both innate and adaptive immune system responses. Experiments carried out in a bid to further understand these effects led to many more discoveries about the applicability of the BCG vaccine for the prevention, diagnosis, and treatment of certain disease conditions. As we approach the second century since the discovery of the vaccine, we believe it is timely to review these interesting applications of the BCG vaccine, such as in the prevention of diabetes, atherosclerosis, and leukemia; the diagnosis of Kawasaki disease; and the treatment of multiple sclerosis, non-muscle invading bladder cancer, and stage III melanoma. Furthermore, complications associated with the administration of the BCG vaccine to certain groups of patients, including those with severe combined immunodeficiency and HIV, have been well described in literature, and we conclude by describing the mechanisms behind these complications and discuss their implications on vaccination strategies, especially in low-resource settings.
{"title":"Expanded Scope of Bacillus Calmette-Guerin (BCG) Vaccine Applicability in Disease Prophylaxis, Diagnostics, and Immunotherapeutics.","authors":"Oluwafolajimi A Adesanya, Christabel I Uche-Orji, Yeshua A Adedeji, John I Joshua, Adeniyi A Adesola, Chibuike J Chukwudike","doi":"10.1097/IM9.0000000000000040","DOIUrl":"10.1097/IM9.0000000000000040","url":null,"abstract":"<p><p>Following the discovery of the Bacillus Calmette-Guerin (BCG) vaccine, its efficacy against <i>Mycobacterium tuberculosis</i> was soon established, with several countries adopting universal BCG vaccination schemes for their populations. Soon, however, studies aimed to further establish the efficacy of the vaccine in different populations discovered that the vaccine has a larger effect in reducing mortality rate than could be explained by its effect on tuberculosis alone, which sparked suggestions that the BCG vaccine could have effects on other unrelated or non-mycobacterial pathogens causing diseases in humans. These effects were termed heterologous, non-specific or off-target effects and have been shown to be due to both innate and adaptive immune system responses. Experiments carried out in a bid to further understand these effects led to many more discoveries about the applicability of the BCG vaccine for the prevention, diagnosis, and treatment of certain disease conditions. As we approach the second century since the discovery of the vaccine, we believe it is timely to review these interesting applications of the BCG vaccine, such as in the prevention of diabetes, atherosclerosis, and leukemia; the diagnosis of Kawasaki disease; and the treatment of multiple sclerosis, non-muscle invading bladder cancer, and stage III melanoma. Furthermore, complications associated with the administration of the BCG vaccine to certain groups of patients, including those with severe combined immunodeficiency and HIV, have been well described in literature, and we conclude by describing the mechanisms behind these complications and discuss their implications on vaccination strategies, especially in low-resource settings.</p>","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"144-150"},"PeriodicalIF":0.0,"publicationDate":"2020-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48247643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-14eCollection Date: 2020-12-01DOI: 10.1097/IM9.0000000000000037
Yitian Zhou, Zachariah L Lee, Jun Zhu
Vibrio cholerae, the causative agent of the infectious disease, cholera, is commonly found in brackish waters and infects human hosts via the fecal-oral route. V. cholerae is a master of stress resistance as V. cholerae's dynamic lifestyle across different physical environments constantly exposes it to diverse stressful circumstances. Specifically, V. cholerae has dedicated genetic regulatory networks to sense different environmental cues and respond to these signals. With frequent outbreaks costing a tremendous amount of lives and increased global water temperatures providing more suitable aquatic habitats for V. cholerae, cholera pandemics remain a probable catastrophic threat to humanity. Understanding how V. cholerae copes with different environmental stresses broadens our repertoire of measures against infectious diseases and expands our general knowledge of prokaryotic stress responses. In this review, we summarize the regulatory mechanisms of how V. cholerae fights against stresses in vivo and in vitro.
{"title":"On or Off: Life-Changing Decisions Made by <i>Vibrio cholerae</i> Under Stress.","authors":"Yitian Zhou, Zachariah L Lee, Jun Zhu","doi":"10.1097/IM9.0000000000000037","DOIUrl":"10.1097/IM9.0000000000000037","url":null,"abstract":"<p><p><i>Vibrio cholerae</i>, the causative agent of the infectious disease, cholera, is commonly found in brackish waters and infects human hosts via the fecal-oral route. <i>V. cholerae</i> is a master of stress resistance as <i>V. cholerae's</i> dynamic lifestyle across different physical environments constantly exposes it to diverse stressful circumstances. Specifically, <i>V. cholerae</i> has dedicated genetic regulatory networks to sense different environmental cues and respond to these signals. With frequent outbreaks costing a tremendous amount of lives and increased global water temperatures providing more suitable aquatic habitats for <i>V. cholerae</i>, cholera pandemics remain a probable catastrophic threat to humanity. Understanding how <i>V. cholerae</i> copes with different environmental stresses broadens our repertoire of measures against infectious diseases and expands our general knowledge of prokaryotic stress responses. In this review, we summarize the regulatory mechanisms of how <i>V. cholerae</i> fights against stresses in vivo and in vitro.</p>","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"127-135"},"PeriodicalIF":0.0,"publicationDate":"2020-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61737673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-06eCollection Date: 2020-12-01DOI: 10.1097/IM9.0000000000000036
Susanna K P Lau, Zirong He, Ken P K Lin, Patrick C Y Woo
{"title":"Sex Bias in Sample Collections From Bats, the Culprit of SARS Coronavirus, SARS-Coronavirus-2, and Other Emerging Viruses.","authors":"Susanna K P Lau, Zirong He, Ken P K Lin, Patrick C Y Woo","doi":"10.1097/IM9.0000000000000036","DOIUrl":"10.1097/IM9.0000000000000036","url":null,"abstract":"","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"173-174"},"PeriodicalIF":0.0,"publicationDate":"2020-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42020938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-07eCollection Date: 2020-12-01DOI: 10.1097/IM9.0000000000000035
Bo Tu, Yuening Zhang, Jingfeng Bi, Zhe Xu, Lei Shi, Xin Zhang, Peng Zhao, Dawei Zhang, Guang Yang, Enqiang Qin
Escherichia coli is a prevalent causative pathogen of spontaneous bacterial peritonitis (SBP). In this retrospective study, we investigated the microbiological characteristics and antibiotic susceptibility of E. coli clinical isolates obtained from liver cirrhosis patients suffering from nosocomial SBP. Our results showed that extended-spectrum β-lactamase (ESBL)-producing E. coli accounted for 47% of the cases, while 62% of the isolates were multi-drug resistant (MDR) pathogens. ESBL-producing and MDR isolates showed high incidences of resistance to third-generation cephalosporins, but they displayed susceptibility to carbapenems, β-lactamase inhibitors, and aminoglycosides. Importantly, liver cirrhosis patients with MDR E. coli SBP showed a significantly higher death rate than patients with non-MDR infections (P = 0.021). The 30-day mortality of nosocomial SBP was independently correlated with female gender [odds ratio (OR) = 5.200, 95% confidence interval (CI) = 1.194-22.642], liver failure (OR = 9.609, 95% CI = 1.914-48.225), hepatocellular carcinoma (OR = 8.176, 95% CI = 2.065-32.364), hepatic encephalopathy (OR = 8.176, 95% CI = 2.065-32.364), model of end-stage liver disease score (OR = 1.191, 95% CI = 1.053-1.346), white blood cell count (OR = 0.847, 95% CI = 0.737-0.973), and ascites polymorphonuclear (OR = 95.903, 95% CI = 3.410-2697.356). In conclusion, third-generation cephalosporins may be inappropriate for empiric treatment of nosocomial SBP caused by E. coli, due to the widespread presence of ESBLs and high incidence of MDR pathogens.
摘要大肠杆菌是自发性细菌性腹膜炎(SBP)的常见致病菌。在这项回顾性研究中,我们研究了从肝硬化院内性收缩压患者中获得的大肠杆菌临床分离株的微生物学特征和抗生素敏感性。结果显示,产广谱β-内酰胺酶(ESBL)的大肠杆菌占47%,而62%的分离株为耐多药(MDR)病原体。产esbl和MDR分离株对第三代头孢菌素耐药发生率高,但对碳青霉烯类、β-内酰胺酶抑制剂和氨基糖苷类敏感。重要的是,MDR型大肠杆菌SBP肝硬化患者的死亡率明显高于非MDR型感染患者(P = 0.021)。院内SBP的30天死亡率是独立与女性性别(比值比(或)= 5.200,95%可信区间(CI) = 1.194 - -22.642),肝功能衰竭(或= 9.609,95% CI -48.225 = 1.914),肝细胞癌(或= 8.176,95% CI -32.364 = 2.065),肝性脑病(或= 8.176,95% CI -32.364 = 2.065),终末期肝病评分模型(或= 1.191,95% CI -1.346 = 1.053),白细胞计数(或= 0.847,95% CI = 0.737 - -0.973),腹水多形核(OR = 95.903, 95% CI = 3.410 ~ 2697.356)。综上所述,由于ESBLs的广泛存在和耐多药病原菌的高发,第三代头孢菌素可能不适合经验性治疗大肠杆菌引起的医院性收缩压。
{"title":"Microbiological Characteristics and Antibiotic Sensitivity in Patients with Nosocomial Spontaneous Bacterial Peritonitis Caused by <i>Escherichia coli</i>: A Multicenter Study.","authors":"Bo Tu, Yuening Zhang, Jingfeng Bi, Zhe Xu, Lei Shi, Xin Zhang, Peng Zhao, Dawei Zhang, Guang Yang, Enqiang Qin","doi":"10.1097/IM9.0000000000000035","DOIUrl":"10.1097/IM9.0000000000000035","url":null,"abstract":"<p><p><i>Escherichia coli</i> is a prevalent causative pathogen of spontaneous bacterial peritonitis (SBP). In this retrospective study, we investigated the microbiological characteristics and antibiotic susceptibility of <i>E. coli</i> clinical isolates obtained from liver cirrhosis patients suffering from nosocomial SBP. Our results showed that extended-spectrum β-lactamase (ESBL)-producing <i>E. coli</i> accounted for 47% of the cases, while 62% of the isolates were multi-drug resistant (MDR) pathogens. ESBL-producing and MDR isolates showed high incidences of resistance to third-generation cephalosporins, but they displayed susceptibility to carbapenems, β-lactamase inhibitors, and aminoglycosides. Importantly, liver cirrhosis patients with MDR <i>E. coli</i> SBP showed a significantly higher death rate than patients with non-MDR infections (<i>P</i> = 0.021). The 30-day mortality of nosocomial SBP was independently correlated with female gender [odds ratio (OR) = 5.200, 95% confidence interval (CI) = 1.194-22.642], liver failure (OR = 9.609, 95% CI = 1.914-48.225), hepatocellular carcinoma (OR = 8.176, 95% CI = 2.065-32.364), hepatic encephalopathy (OR = 8.176, 95% CI = 2.065-32.364), model of end-stage liver disease score (OR = 1.191, 95% CI = 1.053-1.346), white blood cell count (OR = 0.847, 95% CI = 0.737-0.973), and ascites polymorphonuclear (OR = 95.903, 95% CI = 3.410-2697.356). In conclusion, third-generation cephalosporins may be inappropriate for empiric treatment of nosocomial SBP caused by <i>E. coli</i>, due to the widespread presence of ESBLs and high incidence of MDR pathogens.</p>","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"167-172"},"PeriodicalIF":0.0,"publicationDate":"2020-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48720831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-07-21eCollection Date: 2020-09-01DOI: 10.1097/IM9.0000000000000034
Prasanth Manohar, Belinda Loh, Sebastian Leptihn
{"title":"Will the Overuse of Antibiotics During the Coronavirus Pandemic Accelerate Antimicrobial Resistance of Bacteria?","authors":"Prasanth Manohar, Belinda Loh, Sebastian Leptihn","doi":"10.1097/IM9.0000000000000034","DOIUrl":"10.1097/IM9.0000000000000034","url":null,"abstract":"","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"87-88"},"PeriodicalIF":0.0,"publicationDate":"2020-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42603147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-07-16eCollection Date: 2020-09-01DOI: 10.1097/IM9.0000000000000033
Xiaoqin Zheng, Lanjuan Li
The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.
{"title":"Potential Therapeutic Options for COVID-19.","authors":"Xiaoqin Zheng, Lanjuan Li","doi":"10.1097/IM9.0000000000000033","DOIUrl":"10.1097/IM9.0000000000000033","url":null,"abstract":"<p><p>The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.</p>","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"89-95"},"PeriodicalIF":2.0,"publicationDate":"2020-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48056130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-24DOI: 10.1097/IM9.0000000000000030
Yichang Shao, Xun Zeng
Abstract Colorectal cancer (CRC) is the cancer occurring in colon and rectum, and is the fourth leading cause of tumor-associated deaths worldwide. As a multi-etiological cancer, CRC could be induced by genetic and environmental factors, including unhealthy diet, irregular lifestyle, inappropriate inflammatory, and the dysbiosis of gut microbiota. Since immunotherapy has been the most popular cancer therapy nowadays, the relationships among gut microbiota, host immune cells and CRC pathogenesis are widely investigated. Scientists constantly tried to figure out the underlying mechanisms involved to support the further therapeutic studies. In this review, we discuss the component shifts of gut microbiota in CRC patients compared with healthy people, summarize how immune cells participate in protecting host from pathogenic microbes, elaborate the molecular mechanisms involved in gut microbiota-associated carcinogenesis of colonic epithelial cells and look into how gut microbiota influence the CRC therapy.
{"title":"Molecular Mechanisms of Gut Microbiota-Associated Colorectal Carcinogenesis","authors":"Yichang Shao, Xun Zeng","doi":"10.1097/IM9.0000000000000030","DOIUrl":"https://doi.org/10.1097/IM9.0000000000000030","url":null,"abstract":"Abstract Colorectal cancer (CRC) is the cancer occurring in colon and rectum, and is the fourth leading cause of tumor-associated deaths worldwide. As a multi-etiological cancer, CRC could be induced by genetic and environmental factors, including unhealthy diet, irregular lifestyle, inappropriate inflammatory, and the dysbiosis of gut microbiota. Since immunotherapy has been the most popular cancer therapy nowadays, the relationships among gut microbiota, host immune cells and CRC pathogenesis are widely investigated. Scientists constantly tried to figure out the underlying mechanisms involved to support the further therapeutic studies. In this review, we discuss the component shifts of gut microbiota in CRC patients compared with healthy people, summarize how immune cells participate in protecting host from pathogenic microbes, elaborate the molecular mechanisms involved in gut microbiota-associated carcinogenesis of colonic epithelial cells and look into how gut microbiota influence the CRC therapy.","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"96 - 106"},"PeriodicalIF":0.0,"publicationDate":"2020-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/IM9.0000000000000030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42911534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-05DOI: 10.1097/IM9.0000000000000029
Babak Javid, Nathalie Q Balaban
{"title":"Impact of Population Mask Wearing on Covid-19 Post Lockdown.","authors":"Babak Javid, Nathalie Q Balaban","doi":"10.1097/IM9.0000000000000029","DOIUrl":"10.1097/IM9.0000000000000029","url":null,"abstract":"","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2020-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45444550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-06eCollection Date: 2020-06-01DOI: 10.1097/IM9.0000000000000025
Kunkai Su, Xin Huang, Kaijin Xu, Weibo Du, Danhua Zhu, Meifang Yang, Wenji Yuan, Lanjuan Li
The pandemic of coronavirus disease 2019 (COVID-19), a respiratory disease caused by a novel severe acute respiratory syndrome coronavirus-2, is causing substantial morbidity and mortality. Along with the respiratory symptoms, underlying diseases in senior patients, such as diabetes, hypertension, and coronary heart disease, are the most common comorbidities, which cause more severe outcomes and even death. During cellular attachment and entry of severe acute respiratory syndrome coronavirus-2, the key protein involved is the angiotensin I converting enzyme 2 (ACE2), which is located on the membrane of host cells. Here, we aim to curate an expression profile of Ace2 and other COVID-19 related genes across the available diabetes murine strains. Based on strictly manual curation and bioinformatics analysis of the publicly deposited expression datasets, Ace2 and other potentially involved genes such as Furin, Tmprss2, Ang, and Ang2 were examined. We found that Ace2 expression is rather ubiquitous in three selected diabetes prone strains (db/db, ob/ob and diet-induced obese). With the most abundant datasets present, the liver shows a medium Ace2 expression level compared with the lungs, pancreatic islets, brain and even T cells. Age is a more critical factor for Ace2 expression in db/db compared with the other two strains. Besides Ace2, the other four host genes showed varied levels of correlation to each other. To accelerate research on the interaction between COVID-19 and underlying diseases, the Murine4Covid transcriptomics database (www.geneureka.org/Murine4Covid) will facilitate the design of research on COVID-19 and comorbidities.
{"title":"Transcriptomics Curation of SARS-CoV-2 Related Host Genes in Mice With COVID-19 Comorbidity: A Pilot Study.","authors":"Kunkai Su, Xin Huang, Kaijin Xu, Weibo Du, Danhua Zhu, Meifang Yang, Wenji Yuan, Lanjuan Li","doi":"10.1097/IM9.0000000000000025","DOIUrl":"10.1097/IM9.0000000000000025","url":null,"abstract":"<p><p>The pandemic of coronavirus disease 2019 (COVID-19), a respiratory disease caused by a novel severe acute respiratory syndrome coronavirus-2, is causing substantial morbidity and mortality. Along with the respiratory symptoms, underlying diseases in senior patients, such as diabetes, hypertension, and coronary heart disease, are the most common comorbidities, which cause more severe outcomes and even death. During cellular attachment and entry of severe acute respiratory syndrome coronavirus-2, the key protein involved is the angiotensin I converting enzyme 2 (ACE2), which is located on the membrane of host cells. Here, we aim to curate an expression profile of <i>Ace2</i> and other COVID-19 related genes across the available diabetes murine strains. Based on strictly manual curation and bioinformatics analysis of the publicly deposited expression datasets, <i>Ace2</i> and other potentially involved genes such as <i>Furin</i>, <i>Tmprss2</i>, <i>Ang</i>, and <i>Ang2</i> were examined. We found that <i>Ace2</i> expression is rather ubiquitous in three selected diabetes prone strains (db/db, ob/ob and diet-induced obese). With the most abundant datasets present, the liver shows a medium <i>Ace2</i> expression level compared with the lungs, pancreatic islets, brain and even T cells. Age is a more critical factor for <i>Ace2</i> expression in db/db compared with the other two strains. Besides <i>Ace2</i>, the other four host genes showed varied levels of correlation to each other. To accelerate research on the interaction between COVID-19 and underlying diseases, the Murine4Covid transcriptomics database (www.geneureka.org/Murine4Covid) will facilitate the design of research on COVID-19 and comorbidities.</p>","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"42-47"},"PeriodicalIF":0.0,"publicationDate":"2020-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46949773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-05DOI: 10.1097/IM9.0000000000000026
Sisi Huang, Anding Zhu, Yan Wang, Yancong Xu, Lu Li, Dexing Kong
Background: Regarding to the actual situation of the new coronavirus disease 2019 epidemic, social factors should be taken into account and the increasing growth trend of confirmed populations needs to be explained. A proper model needs to be established, not only to simulate the epidemic, but also to evaluate the future epidemic situation and find a pilot indicator for the outbreak.
Methods: The original susceptible-infectious-recover model is modified into the susceptible-infectious-quarantine-confirm-recover combined with social factors (SIDCRL) model, which combines the natural transmission with social factors such as external interventions and isolation. The numerical simulation method is used to imitate the change curve of the cumulative number of the confirmed cases and the number of cured patients. Furthermore, we investigate the relationship between the suspected close contacts (SCC) and the final outcome of the growth trend of confirmed cases with a simulation approach.
Results: This article selects four representative countries, that is, China, South Korea, Italy, and the United States, and gives separate numerical simulations. The simulation results of the model fit the actual situation of the epidemic development and reasonable predictions are made. In addition, it is analyzed that the increasing number of SCC contributes to the epidemic outbreak and the prediction of the United States based on the population of the SCC highlights the importance of external intervention and active prevention measures.
Conclusions: The simulation of the model verifies its reliability and stresses that observable variable SCC can be taken as a pilot indicator of the coronavirus disease 2019 pandemic.
{"title":"Suspected Close Contacts as the Pilot Indicator of the Growth Trend of Confirmed Population During the COVID-19 Pandemic: A Simulation Approach.","authors":"Sisi Huang, Anding Zhu, Yan Wang, Yancong Xu, Lu Li, Dexing Kong","doi":"10.1097/IM9.0000000000000026","DOIUrl":"10.1097/IM9.0000000000000026","url":null,"abstract":"<p><strong>Background: </strong>Regarding to the actual situation of the new coronavirus disease 2019 epidemic, social factors should be taken into account and the increasing growth trend of confirmed populations needs to be explained. A proper model needs to be established, not only to simulate the epidemic, but also to evaluate the future epidemic situation and find a pilot indicator for the outbreak.</p><p><strong>Methods: </strong>The original susceptible-infectious-recover model is modified into the susceptible-infectious-quarantine-confirm-recover combined with social factors (SIDCRL) model, which combines the natural transmission with social factors such as external interventions and isolation. The numerical simulation method is used to imitate the change curve of the cumulative number of the confirmed cases and the number of cured patients. Furthermore, we investigate the relationship between the suspected close contacts (SCC) and the final outcome of the growth trend of confirmed cases with a simulation approach.</p><p><strong>Results: </strong>This article selects four representative countries, that is, China, South Korea, Italy, and the United States, and gives separate numerical simulations. The simulation results of the model fit the actual situation of the epidemic development and reasonable predictions are made. In addition, it is analyzed that the increasing number of SCC contributes to the epidemic outbreak and the prediction of the United States based on the population of the SCC highlights the importance of external intervention and active prevention measures.</p><p><strong>Conclusions: </strong>The simulation of the model verifies its reliability and stresses that observable variable SCC can be taken as a pilot indicator of the coronavirus disease 2019 pandemic.</p>","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2020-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41914273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}